Parmax Pharma share news, announcements and annual reports
BSE: 540359Pharmaceuticals & BiotechnologySmall Cap
Parmax Pharma Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Mar 2017
Last close ₹135.05down ₹1.35 (0.99%)
Share price at the BSE close on 26 Oct 2026. Previous close ₹136.40.
26 Oct: open ₹135.05, high ₹135.05, low ₹135.05
52-week range of traded prices to 26 Oct 2026
₹22.60Low, 25 Mar 2026₹139.10High, 5 Oct 2026
- Under BSE's graded surveillance, stage 0, on the list for 28 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹93 Cr4,411th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business.
- Net worth zero or below
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −70.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- Net worth zero or below
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 657
Parmax Pharma board meetings
107 filed, newest first. Page 1 of 3.
Aug 2026
11 Aug · Board meeting
Meeting on 14 Aug 2026: quarterly results
Jun 2026
8 Jun · Board meeting
3 Jun · Board meeting
Meeting on 8 Jun 2026: preferential issue of shares and issue of warrants1 Jun · Board meeting
Meeting on 2 Jun 2026: audited results
May 2026
Feb 2026
10 Feb · Board meeting
Meeting on 14 Feb 2026: quarterly results
Nov 2025
10 Nov · Board meeting
Meeting on 14 Nov 2025: quarterly results
Aug 2025
8 Aug · Board meeting
Meeting on 14 Aug 2025: quarterly results
May 2025
21 May · Board meeting
Meeting on 30 May 2025: audited results and quarterly results
Feb 2025
6 Feb · Board meeting
Meeting on 14 Feb 2025: quarterly results
Nov 2024
6 Nov · Board meeting
Meeting on 14 Nov 2024: quarterly results
Aug 2024
6 Aug · Board meeting
Meeting on 14 Aug 2024: quarterly results
Jun 2024
May 2024
21 May · Board meeting
Meeting on 30 May 2024: audited results
Feb 2024
14 Feb · Board meeting
7 Feb · Board meeting
Meeting on 14 Feb 2024: quarterly results
Nov 2023
10 Nov · Board meeting
3 Nov · Board meeting
Meeting on 10 Nov 2023: quarterly results
Aug 2023
14 Aug · Board meeting
7 Aug · Board meeting
Meeting on 14 Aug 2023: quarterly results
May 2023
23 May · Board meeting
Meeting on 30 May 2023: audited results
Feb 2023
6 Feb · Board meeting
Meeting on 11 Feb 2023: quarterly results
Nov 2022
7 Nov · Board meeting
Meeting on 12 Nov 2022: quarterly results
Aug 2022
4 Aug · Board meeting
Meeting on 12 Aug 2022: quarterly results